Earth Science Tech Inc. (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, has completed the acquisition of Zoolzy LLC, a wholesale distributor of active pharmaceutical ingredients (APIs) and finished FDA-approved prescription products. The move is poised to create value across three key growth drivers: expanding overall profit margins, broadening access to new ingredients, and enabling entry into the veterinary market.
Zoolzy, based in Doral, Florida, operates from a 3,684-square-foot facility and specializes in the distribution of APIs and finished pharmaceuticals. According to the company, the acquisition will complement ETST's compounding pharmacies by allowing them to secure essential raw materials at highly competitive wholesale pricing. This is expected to significantly increase the company's overall profit margins. Additionally, the acquisition expands ETST's access to a wider range of ingredients and finished products, which can be integrated into its telehealth and pharmacy fulfillment platforms.
One of the most notable aspects of this acquisition is its potential to open up the veterinary market for ETST. APIs and finished prescription products are not only used in human medicine but also in veterinary applications. By gaining access to Zoolzy's distribution capabilities, ETST can now explore opportunities in animal health, a sector that has been growing steadily. This diversification could help the company mitigate risks associated with relying solely on human healthcare markets.
Earth Science Tech's decision to acquire Zoolzy reflects a strategic effort to seize opportunities that broaden its existing telehealth and pharmacy services into complementary verticals. The company has been actively expanding its footprint in the healthcare sector, and this acquisition is a clear indication of its intent to build a more integrated and diversified business model.
The acquisition also positions ETST to better navigate the complex pharmaceutical supply chain. By securing direct access to APIs and finished products, the company can reduce its dependence on third-party suppliers, thereby improving supply chain resilience. This is particularly important in an era where pharmaceutical supply chains have faced disruptions.
Investors have taken note of these developments, as the acquisition is expected to contribute positively to ETST's financial performance. The company's ability to leverage Zoolzy's existing relationships and infrastructure will be key to realizing the anticipated synergies. Management has expressed confidence that the acquisition will not only enhance profitability but also provide a foundation for future growth initiatives.
For more information about Earth Science Tech and its latest updates, interested parties can visit the company's newsroom at https://ibn.fm/ETST.
